Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam - Probes of CYP2C9, CYP1A2, and CYP3A4

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 6, 2007, Pages 833-839

  Lilja, J J ^a   Backman, J T ^a   Neuvonen, P J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DRUG METABOLITE; MIDAZOLAM; TIZANIDINE; WARFARIN; WATER;

ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRANBERRY JUICE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PHYTOCHEMISTRY; PRIORITY JOURNAL; THROMBOPLASTIN TIME; VOLUNTEER;

ADULT; ANTICOAGULANTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BEVERAGES; CLONIDINE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; MALE; MIDAZOLAM; STEREOISOMERISM; VACCINIUM MACROCARPON; WARFARIN;

EID: 34248992947     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100149     Document Type: Article

References (49)

1. Bailey, D.G., Spence, J.D., Munoz, C. & Arnold, J.M.O. Interaction of citrus juices with felodipine and nifedipine. Lancet 337, 268-269 (1991).
2. Bailey, D.G., Malcolm, J., Arnold, O. & Spence, J.D. Grapefruit juice-drug interactions. Br. J. Clin. Pharmacol. 46, 101-110 (1998).
3. Kane, G.C. & Lipsky, J.J. Drug-grapefruit juice interactions. Mayo Clin. Proc. 75, 933-942 (2000).
4. Dresser, G.K. et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther. 71, 11-20 (2002).
5. Lilja, J.J., Backman, J.T., Laitila, J., Luurila, H. & Neuvonen, P.J. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin. Pharmacol. Ther. 73, 192-198 (2003).
6. Lilja, J.J., Juntti-Patinen, L. & Neuvonen, P.J. Orange juice substantially reduces the bioavailability of the beta-adrenergic-blocking agent celiprolol. Clin. Pharmacol. Ther. 75, 184-190 (2004).
7. Suvarna, R., Pirmohamed, M. & Henderson, L. Possible interaction between warfarin and cranberry juice. Br. Med. J. 327, 1454 (2003).
8. Grant, P. Warfarin and cranberry juice: an interaction? J. Heart Valve Dis. 13, 25-26 (2004).
9. Rindone, J.P. & Murphy, T.W. Warfarin-cranberry juice interaction resulting in profound hypothrombinemia and bleeding. Am. J. Ther. 13, 283-284 (2006).
10. Stothers, L. A randomized trial to evaluate effectiveness and cost effectiveness of naturopathic cranberry products as prophylaxis against urinary tract infection in women. Can. J. Urol. 9, 1558-1562 (2002).
11. Raz, R., Chazan, B. & Dan, M. Cranberry juice and urinary tract infection. Clin. Infect. Dis. 38, 1413-1419 (2004).
12. McMurdo, M.E., Bissett, L.Y., Price, R.J., Phillips, G. & Crombie, I.K. Does ingestion of cranberry juice reduce symptomatic urinary tract infections in older people in hospital?. A double-blind, placebo-controlled trial. Age and Ageing 34, 256-261 (2005).
13. Possible interaction between warfarin and cranberry juice. Medicines and Healthcare Products Regulatory Agency/Committee on Safety of Medicines. Cur Probl Pharmacovigilance (2003), 29, 8. Accessed online 23 June 2005, at http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/ cpsept2003.pdf.
14. Grenier, J. et al. Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans. Clin. Pharmacol. Ther. 79, 255-262 (2006).
15. Greenblatt, D.J. et al. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin. Pharmacol. Ther. 79, 125-133 (2006).
16. Kaminsky, L.S. & Zhang, Z.Y. Human P450 metabolism of warfarin. Pharmacol. Ther. 73, 67-74 (1997).
17. Granfors, M.T., Backman, J.T., Laitila, J. & Neuvonen, P.J. Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro. Br. J. Clin. Pharmacol. 57, 349-353 (2004).
18. Granfors, M.T., Backman, J.T., Neuvonen, M., Ahonen, J. & Neuvonen, P.J. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin. Pharmacol. Ther. 75, 331-341 (2004).
19. Granfors, M.T., Backman, J.T., Neuvonen, M. & Neuvonen, P.J. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin. Pharmacol. Ther. 76, 598-606 (2004).
20. Rettie, A.E. et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5, 54-59 (1992).
21. Gorski, J.C., Hall, S.D., Jones, D.R., VandenBranden, M. & Wrighton, S.A. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 47, 1643-1653 (1994).
22. Thummel, K.E. et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J. Pharmacol. Exp. Ther. 271, 549-556 (1994).
23. Chung, E., Nafziger, A.N., Kazierad, D.J. & Bertino, J.S. Jr Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin. Pharmacol. Ther. 79, 350-361 (2006).
24. Howell, A.B. et al. A-Type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity. Phytochemistry 66, 2281-2291 (2005).
25. Chen, H., Zuo, Y. & Deng, Y. Separation and determination of flavonoids and other phenolic compounds in cranberry juice by high-performance liquid chromatography. J. Chromatogr. A 913, 387-395 (2001).
26. Häkkinen, S.H., Kärenlampi, S.O., Heinonen, I.M., Mykkänen, H.M. & Törrönen, A.R. Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. J. Agric. Food Chem. 47, 2274-2279 (1999).
27. Uesawa, Y. & Mohri, K. Effects of cranberry juice on nifedipine pharmacokinetics in rats. J. Pharm. Pharmacol. 58, 1067-1072 (2006).
28. Lown, K.S. et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 99, 2545-2553 (1997).
29. Lilja, J.J., Kivistö, K.T., Backman, J.T. & Neuvonen, P.J. Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life. Eur. J. Clin. Pharmacol. 56, 411-415 (2000).
30. Lundahl, J., Regardh, C.G., Edgar, B. & Johnsson, G. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur. J. Clin. Pharmacol. 49, 61-67 (1995).
31. Lilja, J.J., Kivistö, K.T. & Neuvonen, P.J. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin. Pharmacol. Ther. 68, 384-390 (2000).
32. Toon, S. et al. The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin. Pharmacol. Ther. 39, 15-24 (1986).
33. O'Reilly, R.A. et al. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin. Pharmacol. Ther. 51, 656-667 (1992).
34. Black, D.J. et al. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab. Dispos. 24, 422-428 (1996).
35. Aston, J.L., Lodolce, A.E. & Shapiro, N.L. Interaction between warfarin and cranberry juice. Pharmacotherapy 26, 1314-1319 (2006).
36. Duthie, G.G. et al. Increased salicylate concentrations in urine of human volunteers after consumption of cranberry juice. J. Agric. Food Chem. 53, 2897-2900 (2005).
37. Granfors, M.T., Backman, J.T., Laitila, J. & Neuvonen, P.J. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin. Pharmacol. Ther. 78, 400-411 (2005).
38. Backman, J.T., Karjalainen, M.J., Neuvonen, M., Laitila, J. & Neuvonen, P.J. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br. J. Clin. Pharmacol. 62, 345-357 (2006).
39. Thummel, K.E. et al. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J. Pharmacol. Exp. Ther. 271, 557-566 (1994).
40. Olkkola, K.T., Backman, J.T. & Neuvonen, P.J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 55, 481-485 (1994).
41. Kim, R.B. et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 16, 408-414 (1999).
42. Ahonen, J., Olkkola, K.T. & Neuvonen, P.J. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur. J. Clin. Pharmacol. 51, 415-419 (1997).
43. Backman, J.T., Kivistö, K.T., Olkkola, K.T. & Neuvonen, P.J. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur. J. Clin. Pharmacol. 54, 53-58 (1998).
44. Gurley, B.J. et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin. Pharmacol. Ther. 77, 415-426 (2005).
45. Unge, P. et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br. J. Clin. Pharmacol. 34, 509-512 (1992).
46. McAleer, S.D., Chrystyn, H. & Foondun, A.S. Measurement of the (R)- and (S)-isomers of warfarin in patients undergoing anticoagulant therapy. Chirality 4, 488-493 (1992).
47. Ha, H.R., Rentsch, K.M., Kneer, J. & Vonderschmitt, D.J. Determination of midazolam and its alpha-hydroxy metabolite in human plasma and urine by high-performance liquid chromatography. Ther. Drug Monit. 15, 338-343 (1993).
48. Jabor, V.A., Coelho, E.B., Dos Santos, N.A., Bonato, P.S. & Lanchote, V.L. A highly sensitive LC-MS-MS assay for analysis of midazolam and its major metabolite in human plasma: applications to drug metabolism. J. Chromatogr. B 822, 27-32 (2005).
49. Kähkönen, M.P., Hopia, A.I. & Heinonen, M. Berry phenolics and their antioxidant activity. J. Agric. Food Chem. 49, 4076-4082 (2001).